TP53 and B-cell chronic lymphocytic leukemia: Considering that TP53 mutations or deletions were significantly enriched in the subset of monoallelic del(11q) CLL patients from our NGS analysis and significantly correlated with a worse prognosis, we next investigated the effects of the combination of these alterations in our CRISPR/Cas9‐engineered cell lines.